The effect of co-administration of quercetin supplemented cardiac cardiovascular system with cardiotoxicity of doxorubicin in patients with breast cancer

Phase 2

Completed

• Conditions: Patients with Breast Cancer.; Breast, unspecified

• Registration Number: IRCT20190303042892N1
• Lead Sponsor: Rasht University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 25 March 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

Eligible patients include women aged 21-69 years with sinus rhythm and normal ventricular drainage fraction, normal liver and kidney function, and normal hematology.Previously don`t have any document for chemotherapy or radiotherapy for other types of malignancies. They don`t have CHF. Have not experienced myocardial infarction. Do not suffer from obstruction or heart valves stenosis. They don`t have specific disease or specific drug therapy that affects cardiac function. EF do not have less than 55%.They don`t have cardiovascular disease risk factors , such as hypertension, high fat, and do not include smokers. Women in this clinical trial study are not pregnant and don`t have systolic pressure of less than 90 mmHg.

Exclusion Criteria

Unwillingness to appear in the plan, to make any changes to the treatment or use of the drug. At any time from the implementation of the plan, in the event of any unwanted side effects, the oral supplement will be discontinued and the patient will be excluded from the study.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The cardiac toxicity of doxorubicin is a primary outcome. Timepoint: The amount of troponin is measured one month after the start of chemotherapy and the end of the course. Method of measurement: Troponin test.

Secondary Outcome Measures

Name	Time	Method
Quercetin cardiovascular effect is a secondary consequence. Timepoint: Echocardiography will be done at the end of the chemotherapy (first 3 months), 6 months later and one year later. Method of measurement: Echocardiography.